Filipe A. Moura

1.5k total citations · 2 hit papers
45 papers, 689 citations indexed

About

Filipe A. Moura is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Filipe A. Moura has authored 45 papers receiving a total of 689 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Endocrinology, Diabetes and Metabolism, 21 papers in Cardiology and Cardiovascular Medicine and 12 papers in Surgery. Recurrent topics in Filipe A. Moura's work include Cardiovascular Function and Risk Factors (11 papers), Diabetes Treatment and Management (11 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (8 papers). Filipe A. Moura is often cited by papers focused on Cardiovascular Function and Risk Factors (11 papers), Diabetes Treatment and Management (11 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (8 papers). Filipe A. Moura collaborates with scholars based in Brazil, United States and United Kingdom. Filipe A. Moura's co-authors include Andrei C. Spósito, Luiz Sérgio Fernandes de Carvalho, David A. Morrow, Wilson Nadruz, Erin A. Bohula, Simone Nascimento dos Santos, Hasan K. Siddiqi, Xiaowen Wang, Joshua Lang and Alessandra M. Campos‐Staffico and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of the American College of Cardiology.

In The Last Decade

Filipe A. Moura

39 papers receiving 675 citations

Hit Papers

Olezarsen for Hypertriglyceridemia in Patients at High Ca... 2024 2026 2025 2024 2025 25 50 75 100
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
    2024 102 citations Brian A. Bergmark, Nicholas Marston et al. profile →
  2. Skeletal muscle adiposity, coronary microvascular dysfunction, and adverse cardiovascular outcomes
    2025 14 citations Borek Foldyna, Filipe A. Moura et al. European Heart Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Filipe A. Moura Brazil 15 270 234 181 119 117 45 689
Pilar Calmarza Spain 16 211 0.8× 119 0.5× 171 0.9× 106 0.9× 77 0.7× 61 719
Κ Katogiannis Greece 14 258 1.0× 141 0.6× 96 0.5× 84 0.7× 108 0.9× 59 619
Walter Massón Argentina 15 251 0.9× 285 1.2× 317 1.8× 67 0.6× 144 1.2× 127 904
Alessandro Mengozzi Italy 17 454 1.7× 200 0.9× 177 1.0× 184 1.5× 199 1.7× 50 1.0k
Antonio Ceriello Italy 18 123 0.5× 419 1.8× 111 0.6× 52 0.4× 142 1.2× 26 706
Masahiro Eriguchi Japan 15 214 0.8× 101 0.4× 151 0.8× 59 0.5× 129 1.1× 60 780
Andrzej Mysiak Poland 15 602 2.2× 162 0.7× 187 1.0× 79 0.7× 95 0.8× 69 944
Claudia Agabiti Rosei Italy 20 615 2.3× 224 1.0× 265 1.5× 93 0.8× 68 0.6× 73 1.0k
J Thymis Greece 12 182 0.7× 123 0.5× 70 0.4× 48 0.4× 79 0.7× 49 472
Bas van den Bogaard Netherlands 12 275 1.0× 106 0.5× 177 1.0× 80 0.7× 77 0.7× 31 650

Countries citing papers authored by Filipe A. Moura

Since Specialization
Citations

This map shows the geographic impact of Filipe A. Moura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Filipe A. Moura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Filipe A. Moura more than expected).

Fields of papers citing papers by Filipe A. Moura

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Filipe A. Moura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Filipe A. Moura. The network helps show where Filipe A. Moura may publish in the future.

Co-authorship network of co-authors of Filipe A. Moura

This figure shows the co-authorship network connecting the top 25 collaborators of Filipe A. Moura. A scholar is included among the top collaborators of Filipe A. Moura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Filipe A. Moura. Filipe A. Moura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Felix, Nicole, Lucas Tramujas, Andrea Bellavia, et al.. (2025). A Bayesian Interpretation of CABANA and Other Randomized Controlled Trials for Catheter Ablation in Patients With Atrial Fibrillation. Journal of Cardiovascular Electrophysiology. 36(3). 617–624.
3.
Foldyna, Borek, Filipe A. Moura, Jon Hainer, et al.. (2025). Skeletal muscle adiposity, coronary microvascular dysfunction, and adverse cardiovascular outcomes. European Heart Journal. 46(12). 1112–1123. 14 indexed citations breakdown →
4.
Marston, Nicholas, Brian A. Bergmark, Veronica J. Alexander, et al.. (2025). Design and rationale of the CORE-TIMI 72a and CORE2-TIMI 72b trials of olezarsen in patients with severe hypertriglyceridemia. American Heart Journal. 286. 125–135. 4 indexed citations
5.
Bergmark, Brian A., Nicholas Marston, Thomas A Prohaska, et al.. (2025). Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk: Rationale and design of the Essence–TIMI 73b trial. American Heart Journal. 286. 116–124. 3 indexed citations
6.
Moura, Filipe A., Andrea Bellavia, David D. Berg, et al.. (2024). Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy. Diabetes Obesity and Metabolism. 26(10). 4441–4449. 1 indexed citations
7.
8.
Rosenthal, Michael H., Filipe A. Moura, Sanjay Divakaran, et al.. (2023). Body Composition, Coronary Microvascular Dysfunction, and Future Risk of Cardiovascular Events Including Heart Failure. JACC. Cardiovascular imaging. 17(2). 179–191. 28 indexed citations
9.
Berg, David D., Filipe A. Moura, Andrea Bellavia, et al.. (2023). Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus. Journal of the American College of Cardiology. 81(25). 2391–2402. 5 indexed citations
10.
Moura, Filipe A., David D. Berg, Andrea Bellavia, et al.. (2023). Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes. Diabetes Care. 46(10). 1807–1815. 8 indexed citations
11.
Berg, David Van Den, Filipe A. Moura, Benjamin M. Scirica, et al.. (2022). ASSESSMENT OF ATHEROTHROMBOTIC RISK IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. Journal of the American College of Cardiology. 79(9). 962–962. 2 indexed citations
12.
Nóbrega, Otávio de Tolêdo, Alessandra M. Campos‐Staffico, Daniel Munhoz, et al.. (2021). Defective Allele of the Neuronal Nitric Oxide Synthase Gene Increases Insulin Resistance During Acute Phase of Myocardial Infarction. International Journal of General Medicine. Volume 14. 3669–3676.
13.
Moura, Filipe A., Itamar Raz, Avivit Cahn, et al.. (2021). Abstract 13182: Dapagliflozin and Changes in Metabolic Syndrome in Patients With Type 2 Diabetes: A DECLARE TIMI 58 Sub-Analysis. Circulation. 144(Suppl_1).
14.
Spósito, Andrei C., Alexandre Soares, Daniel Munhoz, et al.. (2021). Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial. Cardiovascular Diabetology. 20(1). 74–74. 61 indexed citations
15.
Moura, Filipe A., et al.. (2020). Role of myocardial strain imaging in surveillance and management of cancer therapeutics‐related cardiac dysfunction: A systematic review. Echocardiography. 38(2). 314–328. 19 indexed citations
16.
Moura, Filipe A., Luiz Sérgio Fernandes de Carvalho, Joaquim Barreto, et al.. (2019). Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy. Revista da Associação Médica Brasileira. 65(1). 70–86. 17 indexed citations
17.
Spósito, Andrei C., et al.. (2019). Statin Short-term Inhibition of Insulin Sensitivity and Secretion During Acute Phase of ST-Elevation Myocardial Infarction. Scientific Reports. 9(1). 16401–16401. 1 indexed citations
18.
Campos‐Staffico, Alessandra M., Ana Paula Costa, Luiz Sérgio Fernandes de Carvalho, et al.. (2019). Omega-3 intake is associated with attenuated inflammatory response and cardiac remodeling after myocardial infarction. Nutrition Journal. 18(1). 29–29. 11 indexed citations
19.
Figueiredo, Valéria Nasser, Filipe A. Moura, & Andrei C. Spósito. (2013). Papel das estatinas na modulação da função endotelial vasomotora na hipertensão e doença coronariana. 40–44. 1 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pilar Calmarza Breakdown of academic impact, for papers by Κ Katogiannis Breakdown of academic impact, for papers by Walter Massón Breakdown of academic impact, for papers by Alessandro Mengozzi Breakdown of academic impact, for papers by Antonio Ceriello Breakdown of academic impact, for papers by Masahiro Eriguchi Breakdown of academic impact, for papers by Andrzej Mysiak Breakdown of academic impact, for papers by Claudia Agabiti Rosei Breakdown of academic impact, for papers by J Thymis Breakdown of academic impact, for papers by Bas van den Bogaard
Rankless by CCL
2026